Past EFORT Congress Exhibitions
PAST EFORT CONGRESS EXHIBITIONS
EFORT understands that in order to assess the relevance of your company exhibiting during 21st EFORT Congress Vienna 2020 – it is often useful to see which companies have exhibited at previous EFORT congresses. For your convenience, therefore, please find the complete exhibitor listings for the following annual congresses via the links below:
- 20th EFORT Annual Congress Lisbon 2019 Exhibitors database.
- 19th EFORT Annual Congress Barcelona 2018 Exhibitors database.
- 18th EFORT Annual Congress Vienna 2017 Exhibitors database.
- 17th EFORT Annual Congress Geneva 2016 Exhibitors database.
- 16th EFORT Annual Congress Prague 2015 Exhibitors database.
- 15thEFORT Annual Congress London 2014 Exhibitors database.
- 14th EFORT Annual Congress Istanbul 2013 Exhibitors database.
For any enquiries relating to exhibition, satellites and sponsorship – please contact by using the official exhibitors and sponsorship contact us online form.
Exhibitors Database 2020
EFORT invites you to browse through the Exhibitors Database of the 21st EFORT Annual Congress Vienna 2020 which represents those exhibitors that have already committed to and confirmed their presence at the 2020 EFORT Congress to be held in Vienna, Austria, from 10 to 12 June 2020.
EFORT Industry Database
SI-BONE® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (SI) joint. SI-BONE developed an innovative, patented implant to fuse the SI joint. The iFuse Implant System® provides a less invasive alternative to traditional sacroiliac (SI) joint fusion surgery and has been used in over 34,000 procedures to date.
The company is managed by an experienced team of executives from Kyphon, Medtronic, INBONE, Saint Francis and several start up orthopedic and spine companies. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.
There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks